Description
Serivan 17 mg Tablet contains Pimavanserin, a selective serotonin inverse agonist and antagonist developed by Incepta Pharmaceuticals Ltd. . It is primarily indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. Pimavanserin works by selectively targeting serotonin 5-HT₂A receptors, with minimal activity at other receptors, thereby reducing psychotic symptoms without exacerbating motor dysfunction. The recommended dosage is 34 mg per day, administered as two 17 mg tablets once daily, with or without food . Common side effects may include nausea, constipation, peripheral edema, gait disturbances, hallucinations, and confusional states. Pimavanserin is contraindicated in patients with known hypersensitivity to the drug. Caution is advised when co-administered with strong CYP3A4 inhibitors or inducers, as these can affect the drug's efficacy and safety profile. The safety and efficacy of Serivan in pediatric patients have not been established, and its use in elderly patients should be carefully considered due to potential risks . Pregnant and breastfeeding women should consult healthcare providers before using this medication, as its effects in these populations are not well-documented. Serivan should be stored at 20°C to 25°C and kept away from light and moisture.
.jpg)
 400MG.jpg)
.jpeg)
.png)
.webp)
.jpeg)
.webp)
.jpg)
.jpg)
.jpg)
.jpeg)
 100 IU 3 ML.webp)
.jpg)
.jpeg)
.webp)
.jpg)
.jpg)
.jpg)
Change Language